← Leaderboards
Janina Baranowska-Kortylewicz
University Of Nebraska Medical Center
$1,258,539
Attributed
$1,258,539
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $301.4K · FY2005–17$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$1,258,539 · 3
By mechanism
R01$896,969 · 1
R21$360,072 · 1
P41$1,498 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Nebraska Medical Center
Same institution · by research overlap
- Michael A Hollingsworth$34,707,253
- Paul M Medin$2,298,059
- Runqing Lu$1,996,782
- David Morris Colcher$6,573,695
- Margaret A Tempero$4,972,214
Others in their field
Top investigators on “Drug Development”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$409,188,846
- Lawrence Corey · Fred Hutchinson Cancer Center$302,964,844
- Wafaa M. El-Sadr · Columbia University Health Sciences$291,216,450
- Constance Ann Benson · University Of California, San Diego$284,817,600
Research focus
Drug DevelopmentNeoplastic CellRadiopharmaceuticalsCancer CellCell LineCellsKillingsPharmaceutical PreparationsStructureBiological HeterogeneityCell Cycle ProgressionBiodistributionAnalogCell ProliferationDna DamageCandidate SelectionBaseDisease-Free SurvivalDisease ProgressionCorrelative StudyDesignDiagnostic ImagingCell CycleChild
Grant awards (6)
Second generation MIBG analogs that cotarget DNA for high risk neuroblastoma$163,669
R21 · FY2017 · CA · contact PI
Second generation MIBG analogs that cotarget DNA for high risk neuroblastoma$196,403
R21 · FY2016 · CA · contact PI
DEVELOPMENT OF DRUGS FOR CANCER TREATMENT$1,498
P41 · FY2008 · RR · contact PI
TK-based methods to improve radioimmunotherapy$294,269
R01 · FY2006 · CA · contact PI
TK-based methods to improve radioimmunotherapy$301,350
R01 · FY2005 · CA
TK-based methods to improve radioimmunotherapy$301,350
R01 · FY2004 · CA